The small molecule WNT/β-catenin inhibitor CWP232291 blocks the growth of castration-resistant prostate cancer by activating the endoplasmic reticulum stress pathway
Abstract Background Androgen receptor (AR)-targeted treatments improve the survival of castration-resistant prostate cancer (CRPC) patients; however, secondary resistance to these agents ultimately occurs in virtually all patients. Therefore, alternative therapeutic targets are urgently needed. Sinc...
Main Authors: | Sahyun Pak, Sejun Park, Yunlim Kim, Jung-Hyuck Park, Chan-Hee Park, Kyoung-June Lee, Choung-soo Kim, Hanjong Ahn |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-08-01
|
Series: | Journal of Experimental & Clinical Cancer Research |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13046-019-1342-5 |
Similar Items
-
Correction to: The small molecule WNT/β-catenin inhibitor CWP232291 blocks the growth of castration-resistant prostate cancer by activating the endoplasmic reticulum stress pathway
by: Sahyun Pak, et al.
Published: (2019-10-01) -
Glucocorticoid receptor and androgen receptor-targeting therapy in patients with castration-resistant prostate cancer
by: Sahyun Pak, et al.
Published: (2022-09-01) -
The endoplasmic reticulum of trypanosomatids: An unrevealed road for chemotherapy
by: Jana Messias Sandes, et al.
Published: (2022-11-01) -
Chemotherapy Resistance Explained through Endoplasmic Reticulum Stress-Dependent Signaling
by: Entaz Bahar, et al.
Published: (2019-03-01) -
Wnt/β-Catenin Inhibition by CWP232291 as a Novel Therapeutic Strategy in Ovarian Cancer
by: Wenyu Wang, et al.
Published: (2022-05-01)